Overcoming Resistance — Omission of Radiotherapy for Low-Risk Breast Cancer

Abstract

In this issue of the Journal, Kunkler and colleagues1 report the highly anticipated 10-year results of the PRIME II trial, which show that omission of radiotherapy did not affect survival after breast-conserving surgery in women 65 years of age or older with T1 or T2 (tumors ≤3 cm in the largest dimension), node-negative, estrogen receptor (ER)–positive breast cancer. These data offer a response to the long-standing problem of overtreatment in older women with low-risk breast cancer.2 The ability to omit radiotherapy is one of many options in a lengthy list that also includes the use of abbreviated radiotherapy regimens and . . .

Topics & Concepts